Skip to main content
Erschienen in: Quality of Life Research 4/2011

01.05.2011

EuroQol (EQ-5D) health utility scores for patients with migraine

verfasst von: Ruifeng Xu, Ralph P. Insinga, Wendy Golden, X. Henry Hu

Erschienen in: Quality of Life Research | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity.

Methods

We examined data for 330 20–65-year-old adults, in good physical health, who had 1–6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods.

Results

The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654).

Conclusions

Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache, 41(7), 646–657.PubMedCrossRef Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache, 41(7), 646–657.PubMedCrossRef
2.
Zurück zum Zitat Linde, M. (2006). Migraine: A review and future directions for treatment. Acta Neurologica Scandinavica, 114(2), 71–83.PubMedCrossRef Linde, M. (2006). Migraine: A review and future directions for treatment. Acta Neurologica Scandinavica, 114(2), 71–83.PubMedCrossRef
3.
Zurück zum Zitat Brown, J. S., Neumann, P. J., Papadopoulos, G., Ruoff, G., Diamond, M., & Menzin, J. (2008). Migraine frequency and health utilities: Findings from a multisite survey. Value Health, 11(2), 315–321.PubMedCrossRef Brown, J. S., Neumann, P. J., Papadopoulos, G., Ruoff, G., Diamond, M., & Menzin, J. (2008). Migraine frequency and health utilities: Findings from a multisite survey. Value Health, 11(2), 315–321.PubMedCrossRef
4.
Zurück zum Zitat Flanagan, W., McIntosh, C. N., Le Petit, C., & Berthelot, J. M. (2006). Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores. Population Health Metrics, 4, 13.PubMedCrossRef Flanagan, W., McIntosh, C. N., Le Petit, C., & Berthelot, J. M. (2006). Deriving utility scores for co-morbid conditions: A test of the multiplicative model for combining individual condition scores. Population Health Metrics, 4, 13.PubMedCrossRef
5.
Zurück zum Zitat Fryback, D. G., Dasbach, E. J., Klein, R., et al. (1993). The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 13(2), 89–102.PubMedCrossRef Fryback, D. G., Dasbach, E. J., Klein, R., et al. (1993). The Beaver Dam health outcomes study: Initial catalog of health-state quality factors. Medical Decision Making, 13(2), 89–102.PubMedCrossRef
6.
Zurück zum Zitat Ko, Y., & Coons, S. J. (2006). Self-reported chronic conditions and EQ-5D index scores in the US adult population. Current Medical Research and Opinion, 22(10), 2065–2071.PubMedCrossRef Ko, Y., & Coons, S. J. (2006). Self-reported chronic conditions and EQ-5D index scores in the US adult population. Current Medical Research and Opinion, 22(10), 2065–2071.PubMedCrossRef
7.
Zurück zum Zitat Kopec, J. A., Schultz, S. E., Goel, V., & Ivan, W. J. (2001). Can the health utilities index measure change? Medical Care, 39(6), 562–574.PubMedCrossRef Kopec, J. A., Schultz, S. E., Goel, V., & Ivan, W. J. (2001). Can the health utilities index measure change? Medical Care, 39(6), 562–574.PubMedCrossRef
8.
Zurück zum Zitat Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.PubMedCrossRef Luo, N., Johnson, J. A., Shaw, J. W., & Coons, S. J. (2009). Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care, 47(1), 53–60.PubMedCrossRef
9.
Zurück zum Zitat Mittmann, N., Trakas, K., Risebrough, N., & Liu, B. A. (1999). Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics, 15(4), 369–376.PubMedCrossRef Mittmann, N., Trakas, K., Risebrough, N., & Liu, B. A. (1999). Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics, 15(4), 369–376.PubMedCrossRef
10.
Zurück zum Zitat Mo, F., Choi, B. C., Li, F. C., & Merrick, J. (2004). Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases. Scientific World Journal, 4, 746–757.PubMed Mo, F., Choi, B. C., Li, F. C., & Merrick, J. (2004). Using Health Utility Index (HUI) for measuring the impact on health-related quality of Life (HRQL) among individuals with chronic diseases. Scientific World Journal, 4, 746–757.PubMed
11.
Zurück zum Zitat Saarni, S. I., Harkanen, T., Sintonen, H., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.PubMedCrossRef Saarni, S. I., Harkanen, T., Sintonen, H., et al. (2006). The impact of 29 chronic conditions on health-related quality of life: A general population survey in Finland using 15D and EQ-5D. Quality of Life Research, 15(8), 1403–1414.PubMedCrossRef
12.
Zurück zum Zitat Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26(4), 410–420.PubMedCrossRef Sullivan, P. W., & Ghushchyan, V. (2006). Preference-based EQ-5D index scores for chronic conditions in the United States. Medical Decision Making, 26(4), 410–420.PubMedCrossRef
13.
Zurück zum Zitat Wells, K. B., & Sherbourne, C. D. (1999). Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Archives of General Psychiatry, 56(10), 897–904.PubMedCrossRef Wells, K. B., & Sherbourne, C. D. (1999). Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Archives of General Psychiatry, 56(10), 897–904.PubMedCrossRef
14.
Zurück zum Zitat Ho, T. W., Mannix, L. K., Fan, X., et al. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 70(16), 1304–1312.PubMedCrossRef Ho, T. W., Mannix, L. K., Fan, X., et al. (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 70(16), 1304–1312.PubMedCrossRef
15.
Zurück zum Zitat (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1), 9–160. (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1), 9–160.
16.
Zurück zum Zitat Lines, C. R., Vandormael, K., & Malbecq, W. (2001). A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain, 93(2), 185–190.PubMedCrossRef Lines, C. R., Vandormael, K., & Malbecq, W. (2001). A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients. Pain, 93(2), 185–190.PubMedCrossRef
17.
Zurück zum Zitat Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.PubMedCrossRef Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.PubMedCrossRef
18.
Zurück zum Zitat Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMedCrossRef Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.PubMedCrossRef
19.
Zurück zum Zitat Ekstrom, W., Nemeth, G., Samnegard, E., Dalen, N., & Tidermark, J. (2009). Quality of life after a subtrochanteric fracture: A prospective cohort study on 87 elderly patients. Injury, 40(4), 371–376.PubMedCrossRef Ekstrom, W., Nemeth, G., Samnegard, E., Dalen, N., & Tidermark, J. (2009). Quality of life after a subtrochanteric fracture: A prospective cohort study on 87 elderly patients. Injury, 40(4), 371–376.PubMedCrossRef
20.
Zurück zum Zitat Ekstrom, W., Miedel, R., Ponzer, S., Hedstrom, M., Samnegard, E., & Tidermark, J. (2009). Quality of life after a stable trochanteric fracture—a prospective cohort study on 148 patients. Journal of Orthopaedic Trauma, 23(1), 39–44.PubMedCrossRef Ekstrom, W., Miedel, R., Ponzer, S., Hedstrom, M., Samnegard, E., & Tidermark, J. (2009). Quality of life after a stable trochanteric fracture—a prospective cohort study on 148 patients. Journal of Orthopaedic Trauma, 23(1), 39–44.PubMedCrossRef
21.
Zurück zum Zitat Slatkowsky-Christensen, B., Mowinckel, P., Loge, J. H., & Kvien, T. K. (2007). Health-related quality of life in women with symptomatic hand osteoarthritis: A comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis and Rheumatism, 57(8), 1404–1409.PubMedCrossRef Slatkowsky-Christensen, B., Mowinckel, P., Loge, J. H., & Kvien, T. K. (2007). Health-related quality of life in women with symptomatic hand osteoarthritis: A comparison with rheumatoid arthritis patients, healthy controls, and normative data. Arthritis and Rheumatism, 57(8), 1404–1409.PubMedCrossRef
22.
Zurück zum Zitat Lipton, R. B., Diamond, S., Reed, M., Diamond, M. L., & Stewart, W. F. (2001). Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache, 41(7), 638–645.PubMedCrossRef Lipton, R. B., Diamond, S., Reed, M., Diamond, M. L., & Stewart, W. F. (2001). Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache, 41(7), 638–645.PubMedCrossRef
23.
Zurück zum Zitat Johnson, J. A., Luo, N., Shaw, J. W., Kind, P., & Coons, S. J. (2005). Valuations of EQ-5D health states: Are the United States and United Kingdom different? Medical Care, 43(3), 221–228.PubMedCrossRef Johnson, J. A., Luo, N., Shaw, J. W., Kind, P., & Coons, S. J. (2005). Valuations of EQ-5D health states: Are the United States and United Kingdom different? Medical Care, 43(3), 221–228.PubMedCrossRef
24.
Zurück zum Zitat Brandes, J. L. (2008). The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache, 48(3), 430–441.PubMedCrossRef Brandes, J. L. (2008). The migraine cycle: Patient burden of migraine during and between migraine attacks. Headache, 48(3), 430–441.PubMedCrossRef
25.
Zurück zum Zitat Barbanti, P., Fabbrini, G., Aurilia, C., Vanacore, N., & Cruccu, G. (2007). A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia, 27(10), 1115–1119.PubMedCrossRef Barbanti, P., Fabbrini, G., Aurilia, C., Vanacore, N., & Cruccu, G. (2007). A case-control study on excessive daytime sleepiness in episodic migraine. Cephalalgia, 27(10), 1115–1119.PubMedCrossRef
26.
Zurück zum Zitat Stronks, D. L., Tulen, J. H., Bussmann, J. B., Mulder, L. J., & Passchier, J. (2004). Interictal daily functioning in migraine. Cephalalgia, 24(4), 271–279.PubMedCrossRef Stronks, D. L., Tulen, J. H., Bussmann, J. B., Mulder, L. J., & Passchier, J. (2004). Interictal daily functioning in migraine. Cephalalgia, 24(4), 271–279.PubMedCrossRef
27.
Zurück zum Zitat Dahlof, C. G., & Dimenas, E. (1995). Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15(1), 31–36.PubMedCrossRef Dahlof, C. G., & Dimenas, E. (1995). Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15(1), 31–36.PubMedCrossRef
28.
Zurück zum Zitat Dahlof, C., Loder, E., Diamond, M., Rupnow, M., Papadopoulos, G., & Mao, L. (2007). The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes, 5, 56.PubMedCrossRef Dahlof, C., Loder, E., Diamond, M., Rupnow, M., Papadopoulos, G., & Mao, L. (2007). The impact of migraine prevention on daily activities: A longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes, 5, 56.PubMedCrossRef
29.
Zurück zum Zitat Diamond, M., Dahlof, C., Papadopoulos, G., Neto, W., & Wu, S. C. (2005). Topiramate improves health-related quality of life when used to prevent migraine. Headache, 45(8), 1023–1030.PubMedCrossRef Diamond, M., Dahlof, C., Papadopoulos, G., Neto, W., & Wu, S. C. (2005). Topiramate improves health-related quality of life when used to prevent migraine. Headache, 45(8), 1023–1030.PubMedCrossRef
30.
Zurück zum Zitat Diener, H. C., Agosti, R., Allais, G., et al. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 6(12), 1054–1062.PubMedCrossRef Diener, H. C., Agosti, R., Allais, G., et al. (2007). Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 6(12), 1054–1062.PubMedCrossRef
31.
Zurück zum Zitat Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., & Goadsby, P. J. (2007). Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 27(7), 814–823.PubMedCrossRef Diener, H. C., Bussone, G., Van Oene, J. C., Lahaye, M., Schwalen, S., & Goadsby, P. J. (2007). Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia, 27(7), 814–823.PubMedCrossRef
32.
Zurück zum Zitat Dodick, D. W., Silberstein, S., Saper, J., et al. (2007). The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache, 47(10), 1398–1408.PubMedCrossRef Dodick, D. W., Silberstein, S., Saper, J., et al. (2007). The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache, 47(10), 1398–1408.PubMedCrossRef
33.
Zurück zum Zitat Schrader, H., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ, 322(7277), 19–22.PubMedCrossRef Schrader, H., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2001). Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ, 322(7277), 19–22.PubMedCrossRef
34.
Zurück zum Zitat Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA, 289(1), 65–69.PubMedCrossRef Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003). Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA, 289(1), 65–69.PubMedCrossRef
35.
Zurück zum Zitat Attema, A. E., & Brouwer, W. B. (2010). On the (not so) constant proportional trade-off in TTO. Quality of Life Research, 19(4), 489–497.PubMedCrossRef Attema, A. E., & Brouwer, W. B. (2010). On the (not so) constant proportional trade-off in TTO. Quality of Life Research, 19(4), 489–497.PubMedCrossRef
36.
Zurück zum Zitat Stalmeier, P. F., Lamers, L. M., Busschbach, J. J., & Krabbe, P. F. (2007). On the assessment of preferences for health and duration: Maximal endurable time and better than dead preferences. Medical Care, 45(9), 835–841.PubMedCrossRef Stalmeier, P. F., Lamers, L. M., Busschbach, J. J., & Krabbe, P. F. (2007). On the assessment of preferences for health and duration: Maximal endurable time and better than dead preferences. Medical Care, 45(9), 835–841.PubMedCrossRef
37.
Zurück zum Zitat Wright, D. R., Wittenberg, E., Swan, J. S., Miksad, R. A., & Prosser, L. A. (2009). Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics, 27(9), 713–723.PubMedCrossRef Wright, D. R., Wittenberg, E., Swan, J. S., Miksad, R. A., & Prosser, L. A. (2009). Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics, 27(9), 713–723.PubMedCrossRef
Metadaten
Titel
EuroQol (EQ-5D) health utility scores for patients with migraine
verfasst von
Ruifeng Xu
Ralph P. Insinga
Wendy Golden
X. Henry Hu
Publikationsdatum
01.05.2011
Verlag
Springer Netherlands
Erschienen in
Quality of Life Research / Ausgabe 4/2011
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-010-9783-5

Weitere Artikel der Ausgabe 4/2011

Quality of Life Research 4/2011 Zur Ausgabe